2013 Q1 Form 10-K Financial Statement
#000104746913002403 Filed on March 08, 2013
Income Statement
| Concept | 2013 Q1 | 2012 | 2011 Q4 |
|---|---|---|---|
| Revenue | $2.414M | $11.20M | $2.433M |
| YoY Change | -0.78% | 20.91% | -93.55% |
| Cost Of Revenue | $2.330M | $10.78M | $2.360M |
| YoY Change | -0.43% | 18.2% | -65.29% |
| Gross Profit | $80.00K | $430.0K | $80.00K |
| YoY Change | -11.11% | 186.67% | -99.74% |
| Gross Profit Margin | 3.31% | 3.84% | 3.29% |
| Selling, General & Admin | $3.140M | $10.02M | $2.290M |
| YoY Change | 35.34% | 9.03% | -9.49% |
| % of Gross Profit | 3925.0% | 2330.23% | 2862.5% |
| Research & Development | $14.09M | $47.40M | $9.820M |
| YoY Change | 30.84% | 46.11% | 45.7% |
| % of Gross Profit | 17612.5% | 11022.79% | 12275.0% |
| Depreciation & Amortization | $468.0K | $2.047M | $840.0K |
| YoY Change | -13.97% | -8.94% | -16.83% |
| % of Gross Profit | 585.0% | 476.05% | 1050.0% |
| Operating Expenses | $14.09M | $47.40M | $12.46M |
| YoY Change | 30.84% | 46.11% | 27.14% |
| Operating Profit | -$17.40M | -$58.08M | -$12.38M |
| YoY Change | 30.95% | 33.82% | -158.62% |
| Interest Expense | $310.0K | $1.576M | -$350.0K |
| YoY Change | -28.41% | -12.25% | -122.73% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$17.33M | -$59.12M | -$12.73M |
| YoY Change | 28.18% | 31.97% | -156.18% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$17.33M | -$59.12M | -$12.73M |
| YoY Change | 28.18% | 31.96% | -156.18% |
| Net Earnings / Revenue | -717.9% | -527.76% | -523.22% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$3.508M | -$15.36M | -$4.215M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 80.60M shares | 44.15M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2013 Q1 | 2012 | 2011 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $182.4M | $84.00M | $53.31M |
| YoY Change | 98.02% | 57.6% | -12.75% |
| Cash & Equivalents | $75.63M | $24.90M | $11.90M |
| Short-Term Investments | $106.8M | $59.10M | $41.41M |
| Other Short-Term Assets | $2.000M | $1.100M | $1.200M |
| YoY Change | 0.0% | -8.33% | -20.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $100.0K | $0.00 | $200.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $184.5M | $85.10M | $54.68M |
| YoY Change | 95.74% | 55.58% | -13.13% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $7.131M | $7.200M | $9.093M |
| YoY Change | -15.11% | -20.88% | -16.05% |
| Goodwill | $8.965M | $8.965M | |
| YoY Change | 0.0% | ||
| Intangibles | $23.58M | $24.92M | |
| YoY Change | -7.13% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $236.0K | $400.0K | $329.0K |
| YoY Change | -52.8% | 33.33% | -9.37% |
| Total Long-Term Assets | $39.91M | $40.40M | $43.31M |
| YoY Change | -6.1% | -6.7% | -7.84% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $184.5M | $85.10M | $54.68M |
| Total Long-Term Assets | $39.91M | $40.40M | $43.31M |
| Total Assets | $224.4M | $125.5M | $97.99M |
| YoY Change | 64.08% | 28.06% | -10.87% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.451M | $700.0K | $935.0K |
| YoY Change | 390.2% | -22.22% | 0.43% |
| Accrued Expenses | $9.692M | $11.00M | $7.008M |
| YoY Change | 51.44% | 57.14% | 41.98% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $5.600M | $5.600M | $6.100M |
| YoY Change | 5.66% | -8.2% | -54.81% |
| Total Short-Term Liabilities | $18.33M | $17.70M | $14.30M |
| YoY Change | 46.64% | 23.78% | -29.25% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $4.400M | $5.700M | $9.000M |
| YoY Change | -55.56% | -36.67% | 1.12% |
| Other Long-Term Liabilities | $6.668M | $6.300M | $5.966M |
| YoY Change | 4.19% | 5.0% | 6.71% |
| Total Long-Term Liabilities | $6.668M | $12.00M | $5.966M |
| YoY Change | -59.09% | -20.0% | 6.71% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $18.33M | $17.70M | $14.30M |
| Total Long-Term Liabilities | $6.668M | $12.00M | $5.966M |
| Total Liabilities | $29.42M | $29.80M | $29.27M |
| YoY Change | 1.98% | 1.71% | -15.61% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$281.5M | -$205.0M | |
| YoY Change | 27.96% | ||
| Common Stock | $473.7M | $271.1M | |
| YoY Change | 16.49% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $194.9M | $95.80M | $68.72M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $224.4M | $125.5M | $97.99M |
| YoY Change | 64.08% | 28.06% | -10.87% |
Cashflow Statement
| Concept | 2013 Q1 | 2012 | 2011 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$17.33M | -$59.12M | -$12.73M |
| YoY Change | 28.18% | 31.96% | -156.18% |
| Depreciation, Depletion And Amortization | $468.0K | $2.047M | $840.0K |
| YoY Change | -13.97% | -8.94% | -16.83% |
| Cash From Operating Activities | -$17.20M | -$49.78M | -$9.370M |
| YoY Change | 26.94% | 39.6% | 55.91% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $162.0K | $303.0K | -$110.0K |
| YoY Change | 285.71% | -40.47% | -75.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$46.42M | -$16.68M | $8.150M |
| YoY Change | 68.98% | 910.91% | 2.52% |
| Cash From Investing Activities | -$46.58M | -$16.98M | $8.040M |
| YoY Change | 69.32% | 686.11% | 7.06% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $114.2M | $83.78M | |
| YoY Change | 119.89% | 132.58% | |
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 114.5M | 79.76M | 120.0K |
| YoY Change | 120.59% | 180.55% | -98.8% |
| NET CHANGE | |||
| Cash From Operating Activities | -17.20M | -49.78M | -9.370M |
| Cash From Investing Activities | -46.58M | -16.98M | 8.040M |
| Cash From Financing Activities | 114.5M | 79.76M | 120.0K |
| Net Change In Cash | 50.73M | 13.00M | -1.210M |
| YoY Change | 367.56% | -238.45% | -110.56% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$17.20M | -$49.78M | -$9.370M |
| Capital Expenditures | $162.0K | $303.0K | -$110.0K |
| Free Cash Flow | -$17.36M | -$50.08M | -$9.260M |
| YoY Change | 27.74% | 38.47% | 66.25% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2011Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2012Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2011Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
3000000 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2012Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
3000000 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
297000000 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
64359513 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
44210636 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
44210636 | shares |
| CY2012Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
64359513 | shares |
| CY2011Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2011Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
297000000 | shares |
| CY2011 | cldx |
Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
|
110000 | USD |
| CY2010 | cldx |
Revenue From Contracts And Grants
RevenueFromContractsAndGrants
|
220000 | USD |
| CY2011 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
9119000 | USD |
| CY2010 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
6386000 | USD |
| CY2011 | us-gaap |
Revenues
Revenues
|
9265000 | USD |
| CY2010 | us-gaap |
Revenues
Revenues
|
46793000 | USD |
| CY2011 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
32439000 | USD |
| CY2010 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
27650000 | USD |
| CY2011 | us-gaap |
Royalty Expense
RoyaltyExpense
|
9119000 | USD |
| CY2010 | us-gaap |
Royalty Expense
RoyaltyExpense
|
12077000 | USD |
| CY2011 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9193000 | USD |
| CY2011 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1913000 | USD |
| CY2010 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3143000 | USD |
| CY2010 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
53248000 | USD |
| CY2011 | us-gaap |
Interest Expense
InterestExpense
|
1796000 | USD |
| CY2010 | us-gaap |
Interest Expense
InterestExpense
|
1337000 | USD |
| CY2011 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-44799000 | USD |
| CY2010 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2533000 | USD |
| CY2011 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.13 | |
| CY2010 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.08 | |
| CY2011 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39501000 | shares |
| CY2010 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
31868000 | shares |
| CY2011 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-9000 | USD |
| CY2010 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
2000 | USD |
| CY2011 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-90000 | USD |
| CY2010 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
203000 | USD |
| CY2011 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-44898000 | USD |
| CY2010 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-2328000 | USD |
| CY2012 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-59030000 | USD |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-59123000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-58077000 | USD |
| CY2012 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
69279000 | USD |
| CY2012 | us-gaap |
Revenues
Revenues
|
11202000 | USD |
| CY2009Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
73767000 | USD |
| CY2010 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
1014000 | USD |
| CY2010 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2802000 | USD |
| CY2010Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
75255000 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
173000 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
2155000 | USD |
| CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2342000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
163000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
40138000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2298000 | USD |
| CY2012 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
2000 | USD |
| CY2012 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
91000 | USD |
| CY2011 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2248000 | USD |
| CY2010 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2718000 | USD |
| CY2011 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-17000 | USD |
| CY2010 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
14000 | USD |
| CY2011 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
-5000 | USD |
| CY2010 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
4000 | USD |
| CY2011 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
58000 | USD |
| CY2010 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
38000 | USD |
| CY2011 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2342000 | USD |
| CY2010 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2802000 | USD |
| CY2011 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
307000 | USD |
| CY2010 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
728000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-154000 | USD |
| CY2010 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-220000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-241000 | USD |
| CY2010 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
546000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-34000 | USD |
| CY2010 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-5592000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
2076000 | USD |
| CY2010 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1193000 | USD |
| CY2010 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-39382000 | USD |
| CY2011 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
51003000 | USD |
| CY2010 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
42383000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-35658000 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-30372000 | USD |
| CY2011 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
52717000 | USD |
| CY2010 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
56522000 | USD |
| CY2011 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
509000 | USD |
| CY2010 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2100000 | USD |
| CY2011 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
68000 | USD |
| CY2010 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
77000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-2155000 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-16162000 | USD |
| CY2011 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
36023000 | USD |
| CY2010 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1014000 | USD |
| CY2011 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
5000000 | USD |
| CY2010 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
10000000 | USD |
| CY2011 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
12503000 | USD |
| CY2011 | us-gaap |
Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
|
86000 | USD |
| CY2010 | us-gaap |
Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
|
197000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
28434000 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
10817000 | USD |
| CY2011 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
|
-9000 | USD |
| CY2010 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
|
2000 | USD |
| CY2011 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-9388000 | USD |
| CY2010 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-35715000 | USD |
| CY2011 | us-gaap |
Interest Paid
InterestPaid
|
1560000 | USD |
| CY2010 | us-gaap |
Interest Paid
InterestPaid
|
604000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
12998000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
79758000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-16980000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-49782000 | USD |
| CY2010Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
21287000 | USD |
| CY2009Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
57002000 | USD |
| CY2012 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>(1) NATURE OF BUSINESS AND OVERVIEW</b></font></p> <p style="FONT-FAMILY: times"><font size="2">        Celldex Therapeutics, Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase 3 study for the treatment of front-line glioblastoma and a Phase 2 study for the treatment of recurrent glioblastoma and CDX-011, an antibody-drug conjugate which recently completed a randomized Phase 2b study for the treatment of advanced breast cancer. The Company has additional clinical programs, including CDX-1135, a molecule that inhibits a part of the immune system called the complement system, CDX-1127, a therapeutic human antibody for cancer indications, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1401, an APC Targeting Technology™ program for cancer indications.</font></p> <p style="FONT-FAMILY: times"><font size="2">        At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $84.0 million; working capital of $67.4 million; and a Term Loan balance of $11.3 million. The Company incurred a loss of $59.1 million for the year ended December 31, 2012. Net cash used in operations for the year ended December 31, 2012 was $49.8 million. In January 2013, the Company issued 2,433,608 shares of common stock under the Cantor Amendment and raised $17.1 million in net proceeds. In February 2013, the Company issued 13,800,000 shares of common stock in an underwritten public offering and raised $97.0 million, after deducting underwriting fees and estimated offering expenses. The Company believes that the cash, cash equivalents and marketable securities at December 31, 2012, the $17.1 million raised under the Cantor Amendment in January 2013 and the $97.0 million raised in the underwritten public offering in February 2013 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font></p> <p style="FONT-FAMILY: times"><font size="2">        During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company's economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company.</font></p></div> | |
| CY2012 | dei |
Entity Registrant Name
EntityRegistrantName
|
Celldex Therapeutics, Inc. | |
| CY2012 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000744218 | |
| CY2012 | dei |
Document Type
DocumentType
|
10-K | |
| CY2012 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-12-31 | |
| CY2012 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2012 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2012 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2012 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2012 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | |
| CY2012 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2012Q2 | dei |
Entity Public Float
EntityPublicFloat
|
303200000 | USD |
| CY2013Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
80599319 | shares |
| CY2012Q4 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
84000000 | USD |
| CY2012Q4 | cldx |
Working Capital
WorkingCapital
|
67400000 | USD |
| CY2012Q4 | us-gaap |
Secured Debt
SecuredDebt
|
11300000 | USD |
| CY2012 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><i>Use of Estimates</i></font></p> <p style="FONT-FAMILY: times"><font size="2">        The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and use assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p></div> | |
| CY2012 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><i>Concentration of Credit Risk</i></font></p> <p style="FONT-FAMILY: times"><font size="2">        Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest bearing accounts at major financial institutions in excess of insured limits. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has not historically experienced credit losses from its accounts receivable and therefore has not established an allowance for doubtful accounts.</font></p> <p style="FONT-FAMILY: times"><font size="2">        Revenue from Glaxo and Pfizer represented 96% and none for the year ended December 31, 2012, 98% and none for the year ended December 31, 2011 and 14% and 85% for the year ended December 31, 2010 of total Company revenue, respectively.</font></p></div> | |
| CY2011Q4 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
82000 | USD |
| CY2012Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
59065000 | USD |
| CY2012 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
| CY2010 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
1700000 | USD |
| CY2011Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
|
2600000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
|
2600000 | USD |
| CY2012 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5355810 | shares |
| CY2011 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4465034 | shares |
| CY2010 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4382883 | shares |
| CY2012Q4 | us-gaap |
Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
|
58909000 | USD |
| CY2011Q4 | us-gaap |
Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
|
41348000 | USD |
| CY2012Q4 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
164000 | USD |
| CY2011Q4 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
147000 | USD |
| CY2012Q4 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
8000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
19530000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
12325000 | USD |
| CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7205000 | USD |
| CY2012 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2047000 | USD |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
19463000 | USD |
| CY2011Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
10370000 | USD |
| CY2012Q4 | cldx |
Accrued Royalty And License Fees Current
AccruedRoyaltyAndLicenseFeesCurrent
|
1776000 | USD |
| CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
925000 | USD |
| CY2012Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
317000 | USD |
| CY2012Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
373000 | USD |
| CY2011Q4 | cldx |
Accrued Royalty And License Fees Current
AccruedRoyaltyAndLicenseFeesCurrent
|
1179000 | USD |
| CY2011Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2145000 | USD |
| CY2011Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
297000 | USD |
| CY2011Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
352000 | USD |
| CY2012Q4 | us-gaap |
Goodwill
Goodwill
|
8965000 | USD |
| CY2011Q4 | cldx |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
28248000 | USD |
| CY2012Q4 | cldx |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
27596000 | USD |
| CY2012Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
23833000 | USD |
| CY2012 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1090000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
1000000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
1000000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
1000000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
1000000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
900000 | USD |
| CY2012Q4 | us-gaap |
Deferred Rent Credit
DeferredRentCredit
|
434000 | USD |
| CY2011Q4 | us-gaap |
Deferred Rent Credit
DeferredRentCredit
|
435000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
4661000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
4661000 | USD |
| CY2012Q4 | cldx |
Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
|
1118000 | USD |
| CY2011Q4 | cldx |
Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
|
510000 | USD |
| CY2012Q4 | us-gaap |
Loans Payable
LoansPayable
|
472000 | USD |
| CY2011Q4 | us-gaap |
Loans Payable
LoansPayable
|
527000 | USD |
| CY2012Q4 | us-gaap |
Other Sundry Liabilities
OtherSundryLiabilities
|
39000 | USD |
| CY2011Q4 | us-gaap |
Other Sundry Liabilities
OtherSundryLiabilities
|
52000 | USD |
| CY2012Q4 | us-gaap |
Other Liabilities
OtherLiabilities
|
6724000 | USD |
| CY2011Q4 | us-gaap |
Other Liabilities
OtherLiabilities
|
6185000 | USD |
| CY2012Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
388000 | USD |
| CY2012Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
6336000 | USD |
| CY2011Q1 | cldx |
Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
|
600000 | USD |
| CY2012 | cldx |
Debt Instrument Amortization Period
DebtInstrumentAmortizationPeriod
|
P15Y | |
| CY2012Q4 | us-gaap |
Debt Instrument Interest Rate At Period End
DebtInstrumentInterestRateAtPeriodEnd
|
0.055 | pure |
| CY2012 | cldx |
Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
|
100000 | USD |
| CY2011Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
11500000 | shares |
| CY2012Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
200000 | USD |
| CY2011Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
200000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
2590000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2303000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
2362000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
2374000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
1221000 | USD |
| CY2012Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
10850000 | USD |
| CY2011 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
2500000 | USD |
| CY2010 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
2500000 | USD |
| CY2012 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
2500000 | USD |
| CY2012 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.50 | pure |
| CY2012 | us-gaap |
Defined Contribution Plan Maximum Annual Contribution Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionPerEmployeePercent
|
0.04 | pure |
| CY2012 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
200000 | USD |
| CY2011 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
200000 | USD |
| CY2010 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
200000 | USD |
| CY2012 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2012 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2011Q2 | cldx |
Common Stock Exercise Of Full Over Allotment Option To Purchase Additional Shares By Underwriter
CommonStockExerciseOfFullOverAllotmentOptionToPurchaseAdditionalSharesByUnderwriter
|
1500000 | shares |
| CY2011Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
33700000 | USD |
| CY2012Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
12075000 | shares |
| CY2012Q1 | cldx |
Common Stock Exercise Of Full Over Allotment Option To Purchase Additional Shares By Underwriter
CommonStockExerciseOfFullOverAllotmentOptionToPurchaseAdditionalSharesByUnderwriter
|
1575000 | shares |
| CY2012Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
43400000 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2298000 | USD |
| CY2011 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2342000 | USD |
| CY2010 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2802000 | USD |
| CY2012 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
-19394000 | USD |
| CY2012 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
-4237000 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit Continuing Operations
IncomeTaxExpenseBenefitContinuingOperations
|
-22205000 | USD |
| CY2012 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | pure |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-20102000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-4237000 | USD |
| CY2012 | cldx |
Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
|
1426000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
22205000 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2011 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
-16204000 | USD |
| CY2011 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
-3131000 | USD |
| CY2011 | us-gaap |
Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
|
-84000 | USD |
| CY2011 | us-gaap |
Income Tax Expense Benefit Continuing Operations
IncomeTaxExpenseBenefitContinuingOperations
|
-19008000 | USD |
| CY2010 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
-1512000 | USD |
| CY2010 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
-779000 | USD |
| CY2010 | us-gaap |
Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
|
-107000 | USD |
| CY2010 | us-gaap |
Income Tax Expense Benefit Continuing Operations
IncomeTaxExpenseBenefitContinuingOperations
|
11526000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-15213000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
1736000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-3131000 | USD |
| CY2011 | cldx |
Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
|
411000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
19008000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-838000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
|
1498000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-779000 | USD |
| CY2010 | cldx |
Income Tax Reconciliation Expiration Of Net Operating Losses And Research And Development Tax Credits
IncomeTaxReconciliationExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
|
13924000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-11526000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
67728000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
20692000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
43226000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3264000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
2156000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
137307000 | USD |
| CY2012Q4 | cldx |
Deferred Tax Liabilities Other Acquired Intangible Assets
DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets
|
4481000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
31002000 | USD |
| CY2012Q4 | cldx |
Deferred Tax Assets In Process Research And Development Intangible Assets
DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets
|
4661000 | USD |
| CY2012Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
9142000 | USD |
| CY2012Q4 | cldx |
Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
|
128165000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
132826000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
58802000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
20285000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
241000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
|
197000 | USD |
| CY2012 | cldx |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
0.15 | pure |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
24897000 | USD |
| CY2012Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
44000 | USD |
| CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1108000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3184000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
2029000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
115499000 | USD |
| CY2011Q4 | cldx |
Deferred Tax Liabilities Other Acquired Intangible Assets
DeferredTaxLiabilitiesOtherAcquiredIntangibleAssets
|
4878000 | USD |
| CY2011Q4 | cldx |
Deferred Tax Assets In Process Research And Development Intangible Assets
DeferredTaxAssetsInProcessResearchAndDevelopmentIntangibleAssets
|
4661000 | USD |
| CY2011Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
9539000 | USD |
| CY2011Q4 | cldx |
Deferred Tax Assets Liabilities Gross
DeferredTaxAssetsLiabilitiesGross
|
105960000 | USD |
| CY2011Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
110621000 | USD |
| CY2012Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
3763000 | USD |
| CY2011Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
3325000 | USD |
| CY2011 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
33695000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
43483000 | USD |
| CY2010 | cldx |
Collaborative Arrangement Milestone Payments Received
CollaborativeArrangementMilestonePaymentsReceived
|
3000000 | USD |
| CY2012Q1 | us-gaap |
Revenues
Revenues
|
2433000 | USD |
| CY2012Q2 | us-gaap |
Revenues
Revenues
|
2009000 | USD |
| CY2012Q3 | us-gaap |
Revenues
Revenues
|
3113000 | USD |
| CY2012Q4 | us-gaap |
Revenues
Revenues
|
3647000 | USD |
| CY2011Q1 | us-gaap |
Revenues
Revenues
|
2516000 | USD |
| CY2011Q2 | us-gaap |
Revenues
Revenues
|
1952000 | USD |
| CY2011Q3 | us-gaap |
Revenues
Revenues
|
2363000 | USD |
| CY2011Q4 | us-gaap |
Revenues
Revenues
|
2433000 | USD |
| CY2012Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13516000 | USD |
| CY2012Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13773000 | USD |
| CY2012Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-15027000 | USD |
| CY2012Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-16807000 | USD |
| CY2011Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10059000 | USD |
| CY2011Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10236000 | USD |
| CY2011Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-11772000 | USD |
| CY2011Q4 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12732000 | USD |
| CY2012Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| CY2012Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.23 | |
| CY2012Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.25 | |
| CY2012Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| CY2011Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.31 | |
| CY2011Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| CY2011Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| CY2011Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.29 | |
| CY2012Q4 | us-gaap |
Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
|
3 | item |
| CY2010Q2 | cldx |
Shelf Registration Statement Amount
ShelfRegistrationStatementAmount
|
150000000 | USD |
| CY2011 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-138000 | USD |
| CY2010 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-1865000 | USD |
| CY2011 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
396000 | USD |
| CY2010 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
5259000 | USD |
| CY2012Q4 | cldx |
Accrued Research And Development Contract Costs Current
AccruedResearchAndDevelopmentContractCostsCurrent
|
7569000 | USD |
| CY2011Q4 | cldx |
Accrued Research And Development Contract Costs Current
AccruedResearchAndDevelopmentContractCostsCurrent
|
3035000 | USD |
| CY2012 | cldx |
Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
|
1426000 | USD |
| CY2011 | cldx |
Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
|
411000 | USD |
| CY2010 | cldx |
Expiration Of Net Operating Losses And Research And Development Tax Credits
ExpirationOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
|
13924000 | USD |
| CY2012 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-22205000 | USD |
| CY2011 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-19008000 | USD |
| CY2010 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
11526000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
708000 | USD |
| CY2011 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
661000 | USD |
| CY2010 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
717000 | USD |
| CY2012Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
424000 | USD |
| CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
745000 | USD |
| CY2012Q4 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
5592000 | USD |
| CY2012Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
5746000 | USD |
| CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
64000 | USD |
| CY2012Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
357094000 | USD |
| CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
2745000 | USD |
| CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-264129000 | USD |
| CY2012 | cldx |
Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
|
146000 | USD |
| CY2012 | cldx |
Revenue From Contracts And Grants
RevenueFromContractsAndGrants
|
281000 | USD |
| CY2012 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
10775000 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
47398000 | USD |
| CY2012 | us-gaap |
Royalty Expense
RoyaltyExpense
|
10775000 | USD |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10016000 | USD |
| CY2012 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
530000 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
1576000 | USD |
| CY2012 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.02 | |
| CY2012 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
57713000 | shares |
| CY2012 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
660000 | USD |
| CY2012 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
6000 | USD |
| CY2012 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
74000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2298000 | USD |
| CY2012 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
226000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
|
-126000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-33000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
95000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
3762000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
594000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
52360000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
69255000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
303000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
218000 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
83784000 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
-3971000 | USD |
| CY2012 | us-gaap |
Repayments Of Other Long Term Debt
RepaymentsOfOtherLongTermDebt
|
55000 | USD |
| CY2012 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
|
2000 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
1384000 | USD |
| CY2012Q1 | cldx |
Value Of Tax Benefits Agreed To Be Sold
ValueOfTaxBenefitsAgreedToBeSold
|
800000 | USD |
| CY2012Q4 | cldx |
Shelf Registration Statement Amount
ShelfRegistrationStatementAmount
|
200000000 | USD |
| CY2012Q1 | cldx |
Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
|
700000 | USD |
| CY2011Q1 | cldx |
Value At Which Tax Benefits Sold
ValueAtWhichTaxBenefitsSold
|
500000 | USD |
| CY2012 | cldx |
Period For Which Base Of Operations Must Be Maintained
PeriodForWhichBaseOfOperationsMustBeMaintained
|
P5Y |
